Thong Q. Le


Thong Q. Le serves as Senior Managing Director and CEO of Accelerator Life Science Partners. Mr. Le has over 20 years of experience identifying, investing, managing, and successfully exiting numerous seed and early-stage investments in the biotechnology sector. He serves as CEO and director of all Accelerator portfolio companies, which currently includes Lydian Neurosciences, Magnolia Neurosciences, and Proniras Corporation. He also served as founding CEO and director of Lodo Therapeutics (acquired by Zymergen Inc.), Petra Pharma (acquired by global pharmaceutical company), and Rodeo Therapeutics (acquired by Amgen Inc.). He is also a director of Acylin Therapeutics, Briotech, and Ravenna Pharmaceuticals.

Prior to joining Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation in Seattle, WA. During his 13-year tenure at WRF Capital, Mr. Le played a significant role in the early sourcing, financing, and development of numerous start-up companies, including Alder Biopharmaceuticals (NASDAQ: ALDR | acquired by H. Lundbeck A/S), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO.L), Hyperion Therapeutics (Nasdaq: HPTX | acquired by Horizon Pharma plc), Lumera (Nasdaq: LMRA), Performant (acquired by Mercury Interactive), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). He also led WRF Capital’s investments in AnswerDash, ARZEDA, Cardeas Pharma, Resolve Therapeutics, and Uptake Medical, all companies where he was actively involved in establishing as a founding or early investor.

Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures.

Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a Bachelor of Arts cum laude in government from Harvard University. He currently serves on the advisory board for the Alexandria Seed Capital Platform and on the executive committees of the Evergreen Venture Capital Association (EVCA) and Washington Global Health Fund. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal.